| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Interim CEO
2 companies
Hagen Heidi serves as a Director at TCRT and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 1 buy and 2 sells. Those positions are worth an estimated $257K at current prices.
The biggest single holding is TCRT (~$257K) as Director. Net of sales, the recent Form 4 record there shows accumulation of 23,770 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | VCEL Vericel Corporation | Director | Sale+OE10b5-1 | 15,000 | $32.41 | $486,150.00 | -32.0% | +24.7% | - | |
| Mar 3, 2025 | VCEL Vericel Corp | Director | Sale+OE10b5-1 | 9,000 | $49.53 | $445,770.00 | -23.9% | -18.3% | -30.5% | |
| Sep 2, 2021 | TCRT Alaunos Therapeutics, Inc. | Director | Buy | 23,770 | $1.76 | $41,835.20 | +19.5% | -28.2% | +63.8% |